<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948596</url>
  </required_header>
  <id_info>
    <org_study_id>SYNCHRO-Open</org_study_id>
    <nct_id>NCT01948596</nct_id>
  </id_info>
  <brief_title>The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO): Open Trial</brief_title>
  <official_title>The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO) : Open Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Medical University, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Japan Society for the Promotion of Science (JSPS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toyama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tokyo Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to examine the efficacy and safety of omega-3 polyunsaturated fatty
      acids for pregnant women with depressive symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maternal depression can have a significant harmful influence on both mothers and children.
      Considering the possibility of adverse effects of antidepressants and previous meta-analyses
      showing the positive effects of omega-3 polyunsaturated fatty acids (PUFAs) supplementation
      in reducing depressive symptoms, omega-3 PUFAs may provide a safe strategy. The investigators
      evaluate efficacy and safety of omega-3 PUFAs for pregnant women with depressive symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total score of the Hamilton Rating Scale for Depression (HAMD)</measure>
    <time_frame>Twelve weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>total score of HAMD</measure>
    <time_frame>4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total scores on the Edinburgh Postnatal Depression Scale (EPDS)</measure>
    <time_frame>Twelve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total score of the Beck Depression Inventory Ⅱ(BDI-Ⅱ)</measure>
    <time_frame>Twelve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major depressive disorder (MDD) as determined by the depression module of the Mini International Neuropsychiatric Interview (MINI)</measure>
    <time_frame>Twelve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>omega-3 fatty acids concentrations in erythrocytes</measure>
    <time_frame>Tweve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain-derived neurotrophic factor (BDNF) in serum</measure>
    <time_frame>Twelve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IF-6 in plasma</measure>
    <time_frame>twelve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxytocin in plasma</measure>
    <time_frame>twelve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-alpha in plasma</measure>
    <time_frame>twelve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1 beta in plasma</measure>
    <time_frame>twelve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phospholipase A2 in plasma</measure>
    <time_frame>twelve weeks, 4-6 weeks after childbirth</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>gestational age</measure>
    <time_frame>at childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>gestational diabetes mellitus</measure>
    <time_frame>4-6 weeks after childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>gestational hypertension or preeclampsia</measure>
    <time_frame>4-6 weeks after childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>induced labour</measure>
    <time_frame>at childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>estimated blood loss</measure>
    <time_frame>at childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>cesarean section</measure>
    <time_frame>at childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>operative vaginal delivery</measure>
    <time_frame>at childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>birthweight</measure>
    <time_frame>at childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>one minute apgar</measure>
    <time_frame>4-6 weeks after childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>5-minute apgar</measure>
    <time_frame>4-6 weeks after childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>neonatal intensive care unit admission</measure>
    <time_frame>4-6 weeks after childbirth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>cholesterol</measure>
    <time_frame>twelve weeks and 4-6 weeks after childbirth</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Pregnancy</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Omega-3 polyunsaturated fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 polyunsaturated fatty acids</intervention_name>
    <arm_group_label>Omega-3 polyunsaturated fatty acids</arm_group_label>
    <other_name>1200mg EPA and 600mg DHA daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pregnant women aged 20 years or older

          2. between 12-24 weeks gestation

          3. a Japanese conversational ability in Japan site or a Mandarin conversational ability
             in Taiwan site to understand the scope of the present trial and to provide written
             consent for study participation

          4. planned to return to the hospital for checkup at 4-6 weeks after childbirth

          5. an Edinburgh Postnatal Depression Scale (EPDS) score is 9 or more

          6. to have good physical health judged by obstetricians.

        Exclusion Criteria:

          1. history and current suspicion of psychosis or bipolar I disorder or substance-related
             disorder or eating disorder or personality disorder

          2. the item of EPDS concerning suicide ideation is 2 or more

          3. other serious psychiatric symptoms such as self-harm behavior or in need of rapid
             psychiatric treatment

          4. difficult to expect a normal birth (ex: fetal malformation etc.)

          5. having a history of bleeding disorder such as von Willebrand's Disease

          6. regular treatment with aspirin or warfarin within the last 3 months

          7. a smoking habit of ≥40 cigarettes per day

          8. regular treatment with ethyl icosapentate or regular consumption of omega-3 PUFA
             supplements within the last 3 months

          9. a habit of eating fish ≥4 times per week.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daisuke Nishi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokyo Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kuan-Pin Su, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical Univeristy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toda Maternity Hospital</name>
      <address>
        <city>Toda</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8402</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Nishi D, Su KP, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Ito H, Isaka K, Hashimoto K, Hamazaki T, Matsuoka YJ. Omega-3 fatty acid supplementation for expectant mothers with depressive symptoms in Japan and Taiwan: An open-label trial. Psychiatry Clin Neurosci. 2016 Jun;70(6):253-4. doi: 10.1111/pcn.12388. Epub 2016 May 6.</citation>
    <PMID>27004997</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2013</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokyo Medical University</investigator_affiliation>
    <investigator_full_name>Daisuke Nishi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>pregnant women</keyword>
  <keyword>depression</keyword>
  <keyword>depressive symptoms</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

